Tag: BBDF
THERANEXUS: New progress for the Batten-1 Program of Theranexus and the BBDF foundation in the juvenile form of Batten disease (CLN3) – 01/05/2023 at 18:00
Lyon, France – Austin, Texas, United States – January 5, 2023 – 6:00 p.m. CET – Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer…
THERANEXUS: Theranexus and the BBDF foundation finalize the recruitment of the phase I/II study evaluating Batten-1 in Batten disease – 09/08/2022 at 18:00
Lyon, France – Austin, Texas, United States – September 8, 2022 – 6:00 p.m. CEST – Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer…
THERANEXUS: THERANEXUS AND THE BBDF FOUNDATION INITIATE RECRUITMENT FOR THE PHASE I/II STUDY IN BATTEN’S DISEASE – 02/03/2022 at 18:00
Lyon, France – Austin, Texas, United States – February 3, 2022 – Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of…